Everolimus EVER

An FDA-approved drug used in organ transplants and certain cancers, also a major focus of research into slowing human aging. Its approved uses are strongly supported by human trials, while low-dose use in healthy older adults for immune or aging benefits is still an early area of research.

Also known as Afinitor, Zortress

Effects Longevity

Routes Oral

Legal status Prescription drug

WADA Not listed

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 10 mg/day (oncology) or 0.75-1.5 mg twice daily (transplant)

Reported range Varies by indication; low-dose intermittent regimens also studied experimentally for immune/aging effects

Route Oral

Frequency Once or twice daily depending on indication

Duration Chronic/ongoing (as prescribed)

FDA-approved mTOR inhibitor (Afinitor/Zortress) for certain cancers and transplant rejection prevention; experimental low-dose 'longevity' use is off-label and unsupervised.

Where this comes from FDA prescribing information; early-phase immune-aging research

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.